KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 10, 2025

Primary Completion Date

November 30, 2028

Study Completion Date

December 31, 2028

Conditions

ColorectalPancreaticNon-small Cell Lung Cancer (NSCLC)

Interventions

DRUG

KRAS-specific Autologous TCR-T cell injection

Drug1 : Fludarabine + Cyclophosphamide Drug2 :Interleukin 2 Drug3 :KRAS-specific Autologous TCR-T cell injection